Zytiga's future is murkier than the other two drugs because Zytiga's patent protection is expiring later this year and that may lead to
the launch of generic drugs that begin to chip away at its market share.
Not exact matches
The company couldn't say whether its
drug price increases have typically occurred before or after a
generic version
launches, but said that once a
generic is available, it would expect to lose so much market share that it «needs to increase the price to keep production
of the
drug viable.»
Teva beats first - quarter expectations but still has the same old problems Copaxone's market share and new
generic launches helped Teva to forecast - beating profit and revenue but problems persistTeva had to make pricing concessions on its flagship multiple sclerosis
drug Copaxone, and now expects a delay in approval
of a key migraine
drug, fremanezumab.